Clinical trial · Observational
Hepatic Resection for Metastatic Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Metastases | — | UNRESOLVED | — |
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hepatic Resection or Ablation with Pancreaticoduodenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PAC with LVLM
- description
- Patients with pancreatic cancer and low-volume liver metastasis
- interventionNames
- Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy
Primary outcomes (3)
- measure
- 90-day mortality
- timeFrame
- 90 days postoperatively
- description
- Number of deaths within 90 days of operation
- measure
- Disease Progression
- timeFrame
- up to 1 year postoperatively
- description
- Time to disease progression
- measure
- Overall Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Subject must be at least 18 years of age and at least the minimum Age of Majority according to applicable State or Country Law * Subject is a surgical candidate, (i.e., is able to undergo general anesthesia and surgical resection for diagnosis of cancer) * The Hepatobiliary Multidisciplinary Committee (HDMC) must approved of this intervention. * Insurance pre-authorization must be received unless the subject decides to pay out of pocket.. * Subject has been informed of the study procedures and the treatment and has signed an informed consent form * less than or equal to 3 liver lesions Exclusion Criteria: * Subject is not a suitable candidate for surgical intervention * The Hepatobiliary Multidisciplinary Committee (HDMC) disapproves of this intervention. * Insurance will not cover the procedure or subject not willing to pay out of pocket. * Pregnant women * Non-English speaking Subjects
References
Publications (1)
- DERIVEDArgentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, Solimando AG, Brunetti O. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Can J Gastroenterol Hepatol. 2020 Oct 9;2020:8679751. doi: 10.1155/2020/8679751. eCollection 2020. PMID 33102398